-
August 16, 2011 to August 16, 2011
Based on our Pharmacor Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments?
This analyst call was held on August 16, 2011. Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
Read More
-
July 6, 2011 to July 6, 2011
Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?
This analyst call was held on July 6, 2011. Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
Read More
-
June 28, 2011 to June 28, 2011
Based on our Pharmacor Ovarian Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled How Will Targeted Therapies Entering the Ovarian Cancer Drug Market Impact Physician Prescribing?
This analyst call was held on June 28, 2011. Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
Read More
-
June 2, 2011 to June 2, 2011
Based on our Pharmacor Hepatitis C Virus advisory service, Decision Resources is offering an exclusive analyst call entitled The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus?
This analyst call was held on June 2, 2011. Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
Read More
-
May 17, 2011 to May 17, 2011
Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled How Will Johnson & Johnson’s Zytiga Compete in the Increasingly Competitive Prostate Cancer Drug Market?
This analyst call was held on May 17, 2011. Contact us to learn how you can purchase this service and access the recording.
Click here to view the invite.
Read More
-
April 21, 2011 to April 21, 2011
Based on our Pharmacor Venous Thromboembolism advisory service, Decision Resources is offering this exclusive analyst call entitled Assessing the Impact of the MAGELLAN Trial – What Does the Future Hold for Xarelto and Other New Anticoagulants for VTE Prevention in Medically Ill Patients?
This analyst call was held on April 21, 2011. Contact us to learn how you can purchase this service and access the recording.
Click here to view the invite.Read More
-
October 22, 2010 to October 22, 2010
You are invited to attend the exclusive Decision Resources Pharmaview competitive assessment entitled Pfizer Adds to Its Pain Franchise and Further Diversifies Its Business with Accretive Financial Deal for King. This session is ONLY available to Pharmaview subscribers.
This analyst call was held on October 22, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
October 20, 2010 to October 20, 2010
Based on our Pharmacor advisory service entitled Prostate Cancer, Decision Resources is offering an exclusive analyst call entitled Turbulent Times in the Prostate Cancer Drug Market – What Are the Commercial Implications of Recent Events? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on October 20, 2010. Contact us to learn how you can purchase this service and access a recorded download of this event.
Click here to view the invite.
Read More
-
October 15, 2010 to October 15, 2010
Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an exclusive analyst call entitled Decision Reversed – After a Preliminary Negative Appraisal, NICE Endorses Herceptin for the Treatment of HER2-Positive Gastric Cancer. Because this presentation features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on October 15, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
October 12, 2010 to October 12, 2010
Based on Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources is offering an exclusive analyst call entitled Biosimilar Monoclonal Antibodies: What will be the Main Drivers and Constraints of Uptake for Oncologists? This analyst call is open ONLY to subscribers of this module of the Biosimilars Advisory Service.
This analyst call was held on October 12, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
October 7, 2010 to October 7, 2010
Based on our Methicillin-resistant Staphylococcus aureus (MRSA) and Hospital-Acquired Infections Pharmacor advisory services, Decision Resources is offering an exclusive analyst call entitled The Rising Threat of Gram-Negative Infections and Multi-Drug Resistant Gram-Negative Strains - News from ICAAC. Because this presentation features major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services.
This analyst call was held on October 7, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
October 5, 2010 to October 5, 2010
Based on Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, Decision Resources is offering an exclusive analyst call entitled Which Biosimilar TNF-alpha Inhibitor Poses the Greatest Threat to Brand Sales? This analyst call is open ONLY to subscribers of this module of the Biosimilars Advisory Service.
This analyst call was held on October 5, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
September 28, 2010 to September 28, 2010
Based on our Pharmacor advisory service entitled Obesity, Decision Resources is offering an exclusive analyst call entitled Yet Another Obesity Agent Fails to Impress FDA Panelists – Will a Suboptimal Risk-to-Benefit Ratio Seal the Fate of Arena’s Lorqess? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call will be held on September 28, 2010. Contact us to learn how you can purchase this service and attend this event.
Click here to view the invite.
Read More
-
September 15, 2010 to September 15, 2010
Based on our Pharmacor advisory service entitled Fibromyalgia, Decision Resources is offering an exclusive analyst call entitled The End of the Line for Jazz Pharmaceuticals’ Fibromyalgia Agent? Assessing the Impact of an FDA Panel’s 20 to 2 Vote Against Sodium Oxybate’s Approval. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call will be held on September 15, 2010. Contact us to learn how you can purchase this service and attend this event.
Click here to view the invite.
Read More
-
September 10, 2010 to September 10, 2010
Based on our Pharmacor advisory service entitled Venous Thromboembolism, Decision Resources is offering an exclusive analyst call entitled Landmark Findings from the European Society of Cardiology Congress - Assessing Xarelto’s Potential to Streamline the Treatment of VTE. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on September 10, 2010. Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.
Read More